Suven Life Sciences, a biopharmaceutical company, witnessed a rise in share price on Thursday after the company received five overseas grants corresponding to their New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases.

The company said, "Suven Life Sciences received the grant of product patent from China, Israel, Mexico, Singapore and Sri Lanka. With these new patents, Suven has a total of seventeen granted patents from China, seven granted patents from Israel, twenty granted patents from Mexico, twenty one granted patents from Singapore and eleven granted patents from Sri Lanka."

"The granted claims of the patents include the class of selective 5-HT compounds discovered by the company and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia," it added.

Venkat Jasti, CEO of Suven said, "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally."

Shares of Suven Life Sciences are trading at Rs 219.00, up Rs 12.15, or 5.87% at the Bombay Stock Exchange (BSE) on Thursday at 11:35 a.m.

Total volume of shares traded on the bourses today was higher by 786.15% to 1,211,159 compared with 22-day average volume of 136,676.